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CLASSIFICATION AND REGRESSION TREES
HELP IN DEVELOPING EMBEDDED EVIDENCE-
AND CONSENSUS-BASED GUIDELINES
Marchetti M1, Barosi G1,Tura S2
1IRCCS Policlinico S. Matteo, Pavia, Italy; 2Policlinico S’Orsola,
Bologna, Italy
OBJECTIVES: Clinical evidence on the best therapies 
for patients with Myelodysplastic Syndromes (MDS) is
incomplete; however, expert opinion is subjective, there-
fore we aimed at imbricating evidence- and experience-
based knowledge as to provide complete and high-level
information to the clinicians dealing with MDS.
METHODS: A systematic review of literature was per-
formed and evidence was graded according to the 
Scottish Intercollegiate Guideline Network. For 4 speciﬁc
interventions (chemotherapy, HLA typing, allogeneic
bone marrow transplantation, wait-and-see) evidence
gaps were completed through direct elicitation of both
clinical experience and transposed evidence from 10 pan-
elists. One hundred and two scenarios were built and the
panelists were asked to score from 1 to 9 the appropri-
ateness of each therapy in each scenario (RAND method).
Appropriateness was inferred from the characteristics of
the scenario (age; IPSS risk class; ECOG score of perfor-
mance status; anemia; cytogenetics) with the technique of
Classiﬁcation and Regression Trees (CRTs) and a treat-
ment algorithm was thus systematically built. ANOVA
helped measuring the variability. RESULTS: Age (F =
572.2) and performance status (F = 5.010) were signiﬁ-
cantly related with the appropriateness of HLA typing
and explained 85% of the variability: the root CRT split
patients according to cutoff ages of 55 and 60 years. The
appropriateness of transplantation also depended on age
(F = 409.1) and performance status (F = 23.63). Indeed,
the ﬁrst split made by the CRT was based on cutoff ages
of 40 and 55 years; further splits were based on the risk
class: patients with INT-2/high risk had higher median
appropriateness scores than INT-1/low risk patients,
however, anemia and age modulated the appropriateness
in INT-1 and low-risk classes. Age (F = 39.4), perfor-
mance status (F = 27.8) and risk class (F = 65.5) explained
79% of the variability in chemotherapy appropriateness:
the CRT ﬁrst splitted patients based upon IPSS risk class
and then upon age (><65yrs). CONCLUSIONS: Guide-
lines can be based on both evidence and consensus of
experts since CRTs are a suitable method for inferring
treatment algorithms.
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HEALTH STATE VALUATIONS IN SUMMARY
MEASURES OF POPULATION HEALTH
Salomon J, Murray CJ, Ustun B, Chatterji S
World Health Organization, Switzerland, Switzerland
OBJECTIVES: A health state valuation constitutes a
scalar index of the level of health associated with a par-
ticular state on a meaningful cardinal scale anchored by
perfect health and death. To date, there have been limited
empirical data on health state valuations collected from
representative sample surveys. WHO has embarked on
measurement of health state valuations as a key compo-
nent of its commitment to routine monitoring and report-
ing on the health levels of its Member States. METHODS:
Household surveys were conducted in representative pop-
ulation samples in ten countries: China, Colombia, Egypt,
Georgia, Indonesia, India, Mexico, Nigeria, Slovakia and
Turkey. Individuals were presented with 10 health states
described by brief labels and asked to describe each state
using standardized questions on six health domains, to
rank order the conditions, and to provide valuations of
the states using a visual analogue scale (VAS). In parallel
studies among highly educated respondents in each 
site, multi-method exercises were conducted in order to
examine methods for adjusting VAS scores to correct for
scale distortions. RESULTS: A total of 345,757 valua-
tions were obtained from 32,781 respondents. For any
given state, there was substantial variation in the descrip-
tions along the six domains. There was considerable
agreement in the mean VAS scores across countries, with
most Pearson’s correlation coefﬁcients greater than 0.8
and an intraclass correlation coefﬁcient of 0.745. A large
proportion of the cross-national variation in VAS scores
was related to differences in the health state descriptions
for each condition. CONCLUSIONS: It is feasible to
collect information on health state valuations in general
population surveys in diverse settings using VAS. New
data collection tools and analytical methods can improve
the cross-population comparability of data on health
measurement and valuation. Further work is needed to
examine variation in health state values both.
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ECONOMIC STUDY OF MALNUTRITION IN
ELDERLY PATIENTS LIVING IN THE
COMMUNITY: USE OF PROPENSITY SCORE TO
ANALYZE OBSERVATIONAL DATA
Schmitt C1,Aussage P1,Arnaud-Battandier F2
1MDS Pharma Services, Sevres, France; 2Nestlé Clinical
Nutrition, Noisiel, France
OBJECTIVE: To assess the cost of malnutrition and
related comorbidities among elderly patients living in the
community and determine the value of nutritional
support. METHODS: Observational, prospective, longi-
tudinal, cohort study with a 12 months follow-up, with
90 general practitioners in France. Two groups of doctors
were selected based on historical prescribing practice: one
with frequent (FNS) and one with limited (LNS) use of
nutritional support. Three hundred seventy-eight elderly
patients aged over 70 living in the community, either at
home or in institutions, at risk of malnutrition or with
established malnutrition. The observational design was
preferred over the randomized option because it would
not have been ethical to ask doctors to refrain from pro-
viding nutritional support when this was their normal
practice. To adjust for baseline differences between
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groups, costs were analyzed using a propensity score
model. Conﬁdence intervals were estimated using boot-
strap methods. RESULTS: Population in the two groups
was balanced for age, gender, weight and body mass
index. The groups differed signiﬁcantly in terms of
housing status (p < 0.05) and nutritional status (p <
0.001). Adjusted costs per patient of hospital care 
(-€551), nursing care (-€145) and other medical care
were signiﬁcantly reduced in the FNS group as compared
to the LNS group, with cost savings of -€723 (90% CI:
-€1.444 to -€43). Including oral supplementation costs,
the total cost savings per patient attributable to nutrition
support were -€195 (90% CI: -€929 to +€478). CON-
CLUSION: Appropriate nutrition diagnosis and support
may contribute to reduce the costs of health care. Propen-
sity score models are a valuable framework for the analy-
sis of cost data, when it is not possible to conduct
randomized studies.
ARTHRITIS & OSTEOPOROSIS—Economic
Outcomes
PAR1
PHARMACOECONOMIC ANALISIS OF THE
TREATMENT WITH LEFLUNOMIDE-
METHOTREXATE OR INFLIXIMAB-
METHOTREXATE IN PATIENTS WITH
RHEUMATOID ARTHRITIS RESISTANT TO
METHOTREXATE
Rubio Terrés C1, Romero F1, Burrell A2, Domínguez-Gil A3
1Aventis Pharma S.A, Madrid, Spain; 2Aventis, Bridgewater, NJ,
USA; 3Hospital Universitario, Salamanca, Spain
OBJECTIVE: To compare the efﬁciency of leﬂunomide-
methotrexate or inﬂiximab-methotrexate in patients 
with rheumatoid arthritis resistant to methotrexate.
METHODS: Cost-minimization pharmacoeconomic
model that compared treatments administered at the 
recommended doses and regimens during a 12-month
period. Use of resources and unit costs were estimated
from Spanish sources. Simple univariate sensitivity analy-
sis was made of the base case. RESULTS: In two 
randomized, placebo-controlled clinical trials available,
the ACR20 and ACR50 responses rates at 6 months 
were 46.2% and 25.4%, respectively, with leﬂunomide-
methotrexate and 50.0% and 27.0%, respectively, with
inﬂiximab-methotrexate (2P = 0.57 and 2P = 0.82). The
estimated cost per patient of annual treatment with
leﬂunomide-methotrexate or inﬂiximab-methotrexate is
€2,823 versus €11,489, respectively (incremental cost of
€8,666). Sensitivity analysis conﬁrmed the robustness 
of the base case, with incremental costs of inﬂiximab-
methotrexate ranging from €7,500 to €9,500. In order to
equalize the costs per patient of these alternatives, the cost
of acquisition of a package of Inﬂiximab would have to
decrease from the present €637.59 to a hypothetical 
cost of €33.10. CONCLUSIONS: The cost per patient 
of twelve months of treatment with the combination of
inﬂiximab-methotrexate is greater than that of leﬂuno-
mide-methotrexate, due mainly to the higher acquisition
cost of Inﬂiximab.
PAR2
THE COST-EFFECTIVENESS ANALYSIS OF
CELECOXIB AND NSAIDS WITH
GASTROPROTECTIVE AGENTS FOR
TREATMENT OF RHEUMATOID ARTHRITIS IN
UKRAINE
Zaliska O
Lviv Medical University, Lviv, Ukraine
OBJECTIVES: To examine the sick rate of rheumatoid
arthritis in Ukraine in 1996 to 2001. Celecoxib is a new
COX-2-inhibitor drug. Randomized controlled clinical
trials—RCCTs showed, that celecoxib is safer than 
non-steroidal anti-ﬂammatory drugs (NSAIDs). To
analyse direct medical costs for treatment celecoxib vs
NSAIDs with gastroprotective agents in patients with
rheumatoid arthritis from the perspective of public health
care in Ukraine. METHODS: A decision tree model in
Ukraine based on the use of clinical data from literature.
Eight RCCTs showed a signifﬁcantly higher incidence of
ulcer—the 6-month rates of ulcer were 5,89% for
NSAIDs vs 1,64% for celecoxib, and for NSAID plus
proton-pump ingibitor (PPI)—1,94%. Only direct costs
associated with three alternatives: celecoxib; NSAID 
only; NSAID plus PPI (six months) were analysed. All
prices are expressed in Ukranian hryvnas (UAH). The
incremental cost-effectiveness ratio was determined.
RESULTS: The sick rate of rheumatoid arthritis from
1996 to 2001 was increased 8,6% per year in Ukraine.
The direct costs of celebrex and NSAID only were com-
parable 905,4 UAH vs 897,5 (1USD = 5,2 UAH), but the
NSAID plus PPI was signiﬁcantly more costly 1216,1
UAH per one patient. The incremental cost-effectiveness
ratio for celecoxib was 1,86 UAH; NSAID plus PPI—80,6
UAH per 1% of ulcer reduction. The total cost of 100
patients treated with celecoxib was 90540 UAH than
NSAIDs plus PPI was 95822 UAH. The threshold analy-
sis suggests that celecoxib would be the dominant therapy
if its cost was to decrease by 58%. CONCLUSIONS: The
treatment with Celecoxib is more effective and safe than
NSAID only, and to be cost-effective than NSAID plus
PPI in Ukraine.
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